The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Manuel Areias Sobrinho Simões

    Autor

  • Ana Paula Soares Dias Ferreira

    Autor

  • Valdemar De Jesus Conde Máximo

    Autor

Participantes de fora da FMUP

  • Canberk, S
  • Gon?alves, J
  • Rios, E
  • Povoa, AA
  • Tastekin, E
  • Uguz, A
  • Aydin, O
  • Ince, U

Unidades de investigação

Abstract

Cytosine modifications at the 5-carbon position play a critical role in gene expression regulation and have been implicated in cancer development. 5-Hydroxymethylcytosine (5hmC), arising from 5-methylcytosine (5-mC) oxidation, has shown promise as a potential malignancy marker due to its depletion in various human cancers. However, its significance in thyroid tumors remains underexplored, primarily due to limited data. In our study, we evaluated 5hmC expression levels by immunohistochemistry in a cohort of 318 thyroid tumors. Our analysis revealed significant correlations between 5hmC staining extension scores and nodule size, vascular invasion, and oncocytic morphology. Nuclear 5hmC staining intensity demonstrated associations with focality, capsule status, extrathyroidal extension, vascular invasion, and oncocytic morphology. Follicular/oncocytic adenomas exhibited higher 5hmC expression than uncertain malignant potential (UMP) or noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), as well as malignant neoplasms, including papillary thyroid carcinomas (PTCs), oncocytic carcinomas (OCAs), follicular thyroid carcinomas (FTCs), and invasive encapsulated follicular variants of PTC (IEFV-PTC). TERT promoter mutation cases showed notably lower values for the 5hmC expression, while RAS (H, N, or K) mutations, particularly HRAS mutations, were associated with higher 5hmC expression. Additionally, we identified, for the first time, a significant link between 5hmC expression and oncocytic morphology. However, despite the merits of these discoveries, we acknowledge that 5hmC currently cannot segregate minimally invasive from widely invasive tumors, although 5hmC levels were lower in wi-FPTCs. Further research is needed to explore the potential clinical implications of 5hmC in thyroid tumors.

Dados da publicação

ISSN/ISSNe:
1559-0097, 1046-3976

Endocrine Pathology  Humana Press

Tipo:
Article
Páginas:
25-39
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 1

Documentos

  • Não há documentos

Métricas

Filiações

Filiações não disponíveis

Keywords

  • Thyroid tumors; Hurthle cell tumor; Oncocytic cell tumors; Epigenetics; 5hmC

Proyectos asociados

The role of 5-hydroxymethylcytosine as a potential epigenetic biomarker in a large series of thyroid neoplasm.

Investigador Principal: Valdemar de Jesus Conde Máximo

Estudo Clínico Académico (Thyroid neoplasm) . 2023

Mitochondrial complex II genetic characterization and enzymatic expression profile in tumours of the adrenal cortex and medulla

Investigador Principal: Valdemar de Jesus Conde Máximo

Estudo Clínico Académico (Mitochondrial) . 2020

Selenium Clinical Supplementation In Autoimmune Thyroid Disease: A Portuguese Survey

Investigador Principal: Ana Paula Soares Dias Ferreira

Estudo Clínico Académico . 2022

Squamous cell carcinogenesis of the skin: Molecular characterization of prognostic therapeutic biomakers

Investigador Principal: Ana Paula Soares Dias Ferreira

Estudo Clínico Académico . 2022

Clinicopathological features and molecular biomarkers? role predicting papillary thyroid cancer patients? outcome: How to personalize and guide surgical treatment

Investigador Principal: Ana Paula Soares Dias Ferreira

Estudo Clínico Académico . 2022

Role of the MITOchondrial fission protein DRP1 as a prognosis and predictive biomarker in the treatment of differentiated thyroid cancer (ROMITO-DRP1)

Investigador Principal: Valdemar de Jesus Conde Máximo

Estudo Clínico Académico . 2022

Fatores do microambiente tumoral no cancro do ovário.

Investigador Principal: Ana Paula Soares Dias Ferreira

Estudo Clínico Académico . 2022

New Biomarkers development, validation and application in Bladder Cancer.

Investigador Principal: Valdemar de Jesus Conde Máximo

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação